Lenvatinib mesylate
Based on 95 publication(s) in Google Scholar
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 857890-39-2
- Formula: C22H23ClN4O7S
- Molecular Weight:522.96
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Lenvatinib mesylate
More- Signal Transduct Target Ther. 2025 Aug 1;10(1):244. [Abstract]
- Nature. 2026 Jun;654(8117):261-271. [Abstract]
- Cancer Cell. 2026 Jun 4:S1535-6108(26)00252-7. [Abstract]
- Drug Resist Updat. 2023 Jul:69:100976. [Abstract]
- Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- J Extracell Vesicles. 2024 Jul;13(7):e12468. [Abstract]
- Adv Sci (Weinh). 2025 May 8:e2501730. [Abstract]
- Adv Sci (Weinh). 2024 Jul 9:e2402327. [Abstract]
- J Exp Clin Cancer Res. 2025 Jan 11;44(1):11. [Abstract]
- Mol Ther. 2023 Jun 7;31(6):1829-1845. [Abstract]
- Biomark Res. 2026 Jan 15;14(1):11. [Abstract]
- MedComm (2020). 2022 Aug 26;3(3):e168. [Abstract]
- Cell Rep Med. 2025 Jul 15;6(7):102208. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cancer Lett. 2026 Feb 9:643:218316. [Abstract]
- Int J Biol Sci. 2023 Apr 23;19(7):2270-2288. [Abstract]
- Adv Healthc Mater. 2024 Nov;13(29):e2401398. [Abstract]
- Cell Death Dis. 2024 Jul 5;15(7):484. [Abstract]
- Angiogenesis. 2025 Feb 3;28(2):13. [Abstract]
- Int J Biol Macromol. 2026 Jan:336:149150. [Abstract]
- Acta Pharmacol Sin. 2026 Jan 1. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Phytomedicine. 2025 May 10:143:156824. [Abstract]
- Phytomedicine. 2024 Jul 25:130:155767. [Abstract]
- EMBO J. 2021 Jun 1;40(11):e106771. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jul 30;17(30):42893-42914. [Abstract]
- Apoptosis. 2024 May 14. [Abstract]
- NPJ Precis Oncol. 2025 Aug 16;9(1):289. [Abstract]
- Biodes Manuf. 17 July 2021.
- J Transl Med. 2023 Jan 9;21(1):9. [Abstract]
- J Transl Med. 2022 Mar 7;20(1):116. [Abstract]
- Biomed Pharmacother. 2022 Jan;145:112391. [Abstract]
- Oncogene. 2024 Oct;43(42):3108-3120. [Abstract]
- Cell Death Discov. 2026 Mar 28. [Abstract]
- J Anal Test. 2025 Sep 25.
- Cell Death Discov. 2021 Nov 18;7(1):359. [Abstract]
- J Med Chem. 2024 Jul 11;67(13):10743-10773. [Abstract]
- Int J Pharm X. 2025 Apr 24:9:100335. [Abstract]
- Ecotoxicol Environ Saf. 2024 Oct 15:285:117031. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Eur J Med Chem. 2025 Dec 6:303:118471. [Abstract]
- Transl Res. 2024 May 24:S1931-5244(24)00107-5. [Abstract]
- Biochem Pharmacol. 2025 Sep 26;242(Pt 3):117367. [Abstract]
- Biochem Pharmacol. 2025 Jun 6:239:117032. [Abstract]
- Mar Drugs. 2024 Sep 28;22(10):444. [Abstract]
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Liver Int. 2023 Jul;43(7):1577-1592. [Abstract]
- Int J Mol Sci. 2025 Apr 18;26(8):3829. [Abstract]
- Int J Mol Sci. 2022 Sep 14;23(18):10677. [Abstract]
- Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Abstract]
- Cell Oncol (Dordr). 2024 Dec;47(6):2439-2460. [Abstract]
- Front Pharmacol. 2024 May 21:15:1394241. [Abstract]
- Int Immunopharmacol. 2025 Mar 26:150:114278. [Abstract]
- Cancer Biol Ther. 2025 Dec;26(1):2532217. [Abstract]
- Cancers (Basel). 2025 Sep 9;17(18):2950. [Abstract]
- Cancers (Basel). 2025 Aug 29;17(17):2846. [Abstract]
- Ann Hepatol. 2025 Jun 1:101932. [Abstract]
- Cancers (Basel). 2023 Oct 22;15(20):5097. [Abstract]
- Bioengineered. 2024 Dec;15(1):2296775. [Abstract]
- J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
- Sci Rep. 2022 Jun 15;12(1):9951. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Cell Signal. 2025 Nov:135:112067. [Abstract]
- Acta Derm Venereol. 2025 Apr 28:105:adv40697. [Abstract]
- Cell Signal. 2023 Nov:111:110828. [Abstract]
- Mol Med Rep. 2025 Nov;32(5):301. [Abstract]
- Med Oncol. 2021 Mar 17;38(4):41. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Med Oncol. 2020 Mar 12;37(4):24. [Abstract]
- Front Oncol. 2022 Sep 8:12:944537. [Abstract]
- Front Oncol. 2021 Jul 13:11:704042. [Abstract]
- Front Biosci (Landmark Ed). 2026 Mar 31;31(4):47715. [Abstract]
- Funct Integr Genomics. 2025 Nov 4;25(1):230. [Abstract]
- Front Biosci (Landmark Ed). 2024 Jan 19;29(1):35. [Abstract]
- Am J Cancer Res. 2023 Nov 15;13(11):5368-5381. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100. [Abstract]
- J Mol Neurosci. 2020 Sep;70(9):1437-1444. [Abstract]
- PLoS One. 2024 Nov 1;19(11):e0308647. [Abstract]
- Fundam Clin Pharmacol. 2021 Oct;35(5):919-929. [Abstract]
- PeerJ. 2023 Jan 25:11:e14610. [Abstract]
- Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):625-635. [Abstract]
- Lasers Surg Med. 2024 Dec;56(10):845-853. [Abstract]
- Acta Pharm. 2024 Sep 14;74(3):441-459. [Abstract]
- Res Sq. 2026 Apr 13.
- bioRxiv. 2025 Dec 5.
- Res Sq. 2024 Nov 18.
- bioRxiv. 2023 Nov 17.
- Research Square Preprint. 2023 Aug 5.
- SSRN. 2023 Apr 24.
- Research Square Print. 2023 Jan 9th,
- J Oncol. 2022 Oct 18;2022:4537343. [Abstract]
- Research Square Print. 2022 Aug.
- Research Square Print. 2022 May.
- Research Square Preprint. 2021 May.
-
IHC
-
Cell Proliferation/Viability Assay
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
All VEGFR Isoforms
More
Biological Activity
|
VEGFR1 22 nM (IC50) |
VEGFR2 4 nM (IC50) |
VEGFR3 5.2 nM (IC50) |
FGFR1 46 nM (IC50) |
FGFR2 |
FGFR3 |
FGFR4 |
PDGFRα 51 nM (IC50) |
PDGFRβ 39 nM (IC50) |
c-Kit 100 nM (IC50) |
RET |
Lenvatinib mesylate (E7080 mesylate) has IC50s of 4, 5.2, 22 nM for VEGFR2(KDR), VEGFR3(Flt-4), and VEGFR1/Flt-1, respectively. Lenvatinib inhibits PDGFRα, PDGFRβ, FGFR1, and KIT with IC50s of 51, 39, 46, 100 nM, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Lenvatinib mesylate (E7080 mesylate) inhibits the growth of H146 tumor at 30 and 100 mg/kg (BID, QDx21) in a dose-dependent manner and causes tumor regression at 100 mg/kg in H146 xenograft model. IHC analysis with anti-CD31 antibody shows that lenvatinib at 100 mg/kg decreases microvessel density more than anti-VEGF antibody and imatinib treatment[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 857890-39-2
-
Appearance Solid
-
Molecular Weight 522.96
-
Formula C22H23ClN4O7S
-
Color White to off-white
-
SMILES
O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.OS(=O)(C)=O
-
Synonyms
E7080 mesylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (95)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma. [Abstract]2025 Aug 1;10(1):244. PMID: 40750772 -
Nature
2026 Jun;654(8117):261-271. PMID: 41986722 -
Cancer Cell
Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. [Abstract]2026 Jun 4:S1535-6108(26)00252-7. PMID: 42242232 -
Drug Resist Updat
Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. [Abstract]2023 Jul:69:100976. PMID: 37210811 -
Nat Commun
Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. [Abstract]2025 Nov 18;16(1):10096. PMID: 41253833 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
J Extracell Vesicles
Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma. [Abstract]2024 Jul;13(7):e12468. PMID: 38944674 -
Adv Sci (Weinh)
PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. [Abstract]2025 May 8:e2501730. PMID: 40344394 -
Adv Sci (Weinh)
Stabilization of TGF-β Receptor 1 by a Receptor-Associated Adaptor Dictates Feedback Activation of the TGF-β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance. [Abstract]2024 Jul 9:e2402327. PMID: 38981014 -
J Exp Clin Cancer Res
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. [Abstract]2025 Jan 11;44(1):11. PMID: 39794830 -
Mol Ther
miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism. [Abstract]2023 Jun 7;31(6):1829-1845. PMID: 37143325 -
Biomark Res
miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC. [Abstract]2026 Jan 15;14(1):11. PMID: 41540504 -
MedComm (2020)
Interferon regulatory factor 1-triggered free ubiquitin protects the intestines against radiation-induced injury via CXCR4/FGF2 signaling. [Abstract]2022 Aug 26;3(3):e168. PMID: 36051984 -
Cell Rep Med
CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma. [Abstract]2025 Jul 15;6(7):102208. PMID: 40592346 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cancer Lett
The deficiency of ALKBH5 promotes lenvatinib resistance and CD8+ T cell exhaustion via accumulation of the cholesterol metabolite 27HC in hepatocellular carcinoma. [Abstract]2026 Feb 9:643:218316. PMID: 41672222 -
Int J Biol Sci
Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma. [Abstract]2023 Apr 23;19(7):2270-2288. PMID: 37151886 -
Adv Healthc Mater
A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells. [Abstract]2024 Nov;13(29):e2401398. PMID: 39359011 -
Cell Death Dis
BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC. [Abstract]2024 Jul 5;15(7):484. PMID: 38969639 -
Angiogenesis
Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization. [Abstract]2025 Feb 3;28(2):13. PMID: 39899169 -
Int J Biol Macromol
Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma. [Abstract]2026 Jan:336:149150. PMID: 41274476 -
Acta Pharmacol Sin
LAMTOR5 promotes hepatoma growth in mice by disrupting LC3-p62-mediated autophagy and preventing p62 proteasome degradation. [Abstract]2026 Jan 1. PMID: 41478881 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Phytomedicine
Ponicidin promotes ferroptosis to enhance treatment sensitivity in Lenvatinib-resistant hepatocellular carcinoma cells through regulation of KEAP1/NRF2. [Abstract]2025 May 10:143:156824. PMID: 40382941 -
Phytomedicine
Dihydrotanshinone I targets ESR1 to induce DNA double-strand breaks and proliferation inhibition in hepatocellular carcinoma. [Abstract]2024 Jul 25:130:155767. PMID: 38833789 -
EMBO J
Inhibition of Syk promotes chemical reprogramming of fibroblasts via metabolic rewiring and H2 S production. [Abstract]2021 Jun 1;40(11):e106771. PMID: 33909912 -
ACS Appl Mater Interfaces
Methacrylated Carrageenan/Gelatin Interpenetrating Network Microspheres Loaded with Targeted Drugs and combined with PD-L1 Inhibitors for Hepatocellular Carcinoma Treatment. [Abstract]2025 Jul 30;17(30):42893-42914. PMID: 40671639 -
Apoptosis
EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis. [Abstract]2024 May 14. PMID: 38743191 -
NPJ Precis Oncol
Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma. [Abstract]2025 Aug 16;9(1):289. PMID: 40819143 -
-
J Transl Med
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. [Abstract]2023 Jan 9;21(1):9. PMID: 36624452 -
J Transl Med
Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population. [Abstract]2022 Mar 7;20(1):116. PMID: 35255940
Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Mar 7;20(1):116. [Abstract]
H&E examination of vehicle and Lenvatinib (10 mg/kg daily by oral gavage)-treated tumors revealed markedly increase tumor necrosis and desmoplasia in the Lenvatinib-treated samples.
-
Biomed Pharmacother
The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib. [Abstract]2022 Jan;145:112391. PMID: 34847475 -
Oncogene
GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma. [Abstract]2024 Oct;43(42):3108-3120. PMID: 39251847 -
Cell Death Discov
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. [Abstract]2026 Mar 28. PMID: 41896541 -
-
Cell Death Discov
Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. [Abstract]2021 Nov 18;7(1):359. PMID: 34795217
Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Nov 18;7(1):359. [Abstract]
Lenvatinib (1000 nM) has demonstrated the ability to significantly inhibit cell proliferation, and knockout of NF1 and DUSP9 significantly blocks the ability of lenvatinib to inhibit cell proliferation as well as the effect on cell number.
-
J Med Chem
Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma. [Abstract]2024 Jul 11;67(13):10743-10773. PMID: 38919032 -
Int J Pharm X
An aptamer-conjugated mesoporous polydopamine formulation for synergistic targeted and photothermal therapy of hepatocellular carcinoma. [Abstract]2025 Apr 24:9:100335. PMID: 40927752 -
Ecotoxicol Environ Saf
Protective role of ghrelin against 6PPD-quinone-induced neurotoxicity in zebrafish larvae (Danio rerio) via the GHSR pathway. [Abstract]2024 Oct 15:285:117031. PMID: 39341137 -
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Eur J Med Chem
Discovery of novel small molecule inhibitor targeting the tumor promoting effect of transcription factor PLAGL2. [Abstract]2025 Dec 6:303:118471. PMID: 41365089 -
Transl Res
2024 May 24:S1931-5244(24)00107-5. PMID: 38797432 -
Biochem Pharmacol
Dual activation of PPARα/γ by bezafibrate triggers PINK1/Parkin-Mediated mitophagy to enhance lenvatinib sensitivity in hepatocellular carcinoma. [Abstract]2025 Sep 26;242(Pt 3):117367. PMID: 41016578 -
Biochem Pharmacol
Molecular Dissection of the AHR-AREG driven EGFR-ERK1/2-CyclinD1 axis in acquired lenvatinib resistance of Hepatocellular carcinoma. [Abstract]2025 Jun 6:239:117032. PMID: 40482839 -
Mar Drugs
New Fusarochromanone Derivatives from the Marine Fungus Fusarium equiseti UBOCC-A-117302. [Abstract]2024 Sep 28;22(10):444. PMID: 39452852 -
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Liver Int
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway. [Abstract]2023 Jul;43(7):1577-1592. PMID: 37208925 -
Int J Mol Sci
Myristoyl-CM4 Exhibits Direct Anticancer Activity and Immune Modulation in Hepatocellular Carcinoma: Evidence from In Vitro and Mouse Model Studies. [Abstract]2025 Apr 18;26(8):3829. PMID: 40332513 -
Int J Mol Sci
Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. [Abstract]2022 Sep 14;23(18):10677. PMID: 36142591 -
Cell Oncol (Dordr)
Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. [Abstract]2025 Apr;48(2):487-504. PMID: 39585643 -
Cell Oncol (Dordr)
GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation. [Abstract]2024 Dec;47(6):2439-2460. PMID: 39718738 -
Front Pharmacol
Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. [Abstract]2024 May 21:15:1394241. PMID: 38835670 -
Int Immunopharmacol
Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma. [Abstract]2025 Mar 26:150:114278. PMID: 39954659 -
Cancer Biol Ther
Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation. [Abstract]2025 Dec;26(1):2532217. PMID: 40653759 -
Cancers (Basel)
Cabozantinib Sensitizes NSCLC Cells to Radiation by Inducing Ferroptosis via STAT3/MCL1/BECN1/SLC7A11 Axis Suppression. [Abstract]2025 Sep 9;17(18):2950. PMID: 41008795 -
Cancers (Basel)
ITGA2 Mediates the Resistance of Hepatocellular Carcinoma to Lenvatinib by Activating the AKT/FOXO3A Signaling Pathway. [Abstract]2025 Aug 29;17(17):2846. PMID: 40940943 -
Ann Hepatol
Data mining reveals novel gene drivers of lenvatinib resistance in hepatocellular carcinoma. [Abstract]2025 Jun 1:101932. PMID: 40460973 -
Cancers (Basel)
Dose Consideration of Lenvatinib's Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. [Abstract]2023 Oct 22;15(20):5097. PMID: 37894463 -
Bioengineered
Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line. [Abstract]2024 Dec;15(1):2296775. PMID: 38184822 -
J Cell Mol Med
Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. [Abstract]2021 Jan;25(1):549-560. PMID: 33210432
Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
The cell viability is measured by CCK-8 assay at different time intervals (24, 48, 72 and 96 h) when cells are cultured with 5 μM Lenvatinib.
Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
The mRNA expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. VEGFR2 mRNA expression is up-regulated in HepG2-LR and Huh7LR cells.
Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]
The protein expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. Western blotting results show the downstream target RAS/MEK/ERK axis of VEGFR2 are obviously up‐regulated in HepG2-LR and Huh7-LR cells compared with their parental cells.
-
Sci Rep
Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study. [Abstract]2022 Jun 15;12(1):9951. PMID: 35705678 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Cell Signal
Melatonin reverses lenvatinib resistance in HCC by regulating the ATF4-NRF1 pathway mediated by ceramide synthase 6. [Abstract]2025 Nov:135:112067. PMID: 40818539 -
Acta Derm Venereol
Possible Clinical Effects of Ketoconazole on Sorafenib-induced Hand-Foot Skin Reaction and Cytoprotection Mechanisms of Antifungal Agents against Multikinase Inhibitor-induced Keratinocyte Toxicity. [Abstract]2025 Apr 28:105:adv40697. PMID: 40289816 -
Cell Signal
2023 Nov:111:110828. PMID: 37517671 -
Mol Med Rep
Aberrant activation of the PI3K/AKT/HIF‑1α pathway promotes glycolysis and lenvatinib resistance in liver cancer. [Abstract]2025 Nov;32(5):301. PMID: 40878941 -
Med Oncol
Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency. [Abstract]2021 Mar 17;38(4):41. PMID: 33730237 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Med Oncol
Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. [Abstract]2020 Mar 12;37(4):24. PMID: 32166604 -
Front Oncol
Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. [Abstract]2022 Sep 8:12:944537. PMID: 36158676 -
Front Oncol
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]2021 Jul 13:11:704042. PMID: 34327143 -
Front Biosci (Landmark Ed)
2026 Mar 31;31(4):47715. PMID: 42052849 -
Funct Integr Genomics
DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway. [Abstract]2025 Nov 4;25(1):230. PMID: 41186842 -
Front Biosci (Landmark Ed)
Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway. [Abstract]2024 Jan 19;29(1):35. PMID: 38287824 -
Am J Cancer Res
Exosomes with IR780 and Lenvatinib loaded on GPC3 single-chain scFv antibodies for targeted hyperthermia and chemotherapy in hepatocellular carcinoma therapy. [Abstract]2023 Nov 15;13(11):5368-5381. PMID: 38058824 -
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]2024 Apr 15:1237:124100. PMID: 38547701 -
J Mol Neurosci
Deferoxamine Ameliorates Compressed Spinal Cord Injury by Promoting Neovascularization in Rats. [Abstract]2020 Sep;70(9):1437-1444. PMID: 32383023 -
PLoS One
A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]2024 Nov 1;19(11):e0308647. PMID: 39485774 -
Fundam Clin Pharmacol
2021 Oct;35(5):919-929. PMID: 33523504 -
PeerJ
Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro. [Abstract]2023 Jan 25:11:e14610. PMID: 36718449 -
Eur J Drug Metab Pharmacokinet
Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors. [Abstract]2021 Sep;46(5):625-635. PMID: 34275128 -
Lasers Surg Med
Study on the Synergistic Mechanism of Photodynamic Therapy Combined With Ferroptosis Inducer to Induce Ferroptosis in Cholangiocarcinoma. [Abstract]2024 Dec;56(10):845-853. PMID: 39468974 -
Acta Pharm
The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver. [Abstract]2024 Sep 14;74(3):441-459. PMID: 39279523 -
-
-
-
-
-
-
-
J Oncol
Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. [Abstract]2022 Oct 18;2022:4537343. PMID: 36304988
Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]
HepG2 and HepG2/R cells are treated with indicated doses of Lenvatinib for 24 h, and cellular viabilities are measured.
Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]
HepG2 and HepG2/R cells are treated with or without Lenvatinib (20 μM) for 24 h, and indicated proteins are measured by western blots.
-
-
-
Solvent & Solubility
DMSO : 30.77 mg/mL (58.84 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 8.33 mg/mL (15.93 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. [Content Brief]
[2]. Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361. [Content Brief]
[3]. 3.Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545. [Content Brief]
[4]. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122(3), 664-671. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9122 mL | 9.5610 mL | 19.1219 mL | 47.8048 mL |
| 5 mM | 0.3824 mL | 1.9122 mL | 3.8244 mL | 9.5610 mL | |
| 10 mM | 0.1912 mL | 0.9561 mL | 1.9122 mL | 4.7805 mL | |
| 15 mM | 0.1275 mL | 0.6374 mL | 1.2748 mL | 3.1870 mL | |
| 20 mM | 0.0956 mL | 0.4780 mL | 0.9561 mL | 2.3902 mL | |
| 25 mM | 0.0765 mL | 0.3824 mL | 0.7649 mL | 1.9122 mL | |
| 30 mM | 0.0637 mL | 0.3187 mL | 0.6374 mL | 1.5935 mL | |
| 40 mM | 0.0478 mL | 0.2390 mL | 0.4780 mL | 1.1951 mL | |
| 50 mM | 0.0382 mL | 0.1912 mL | 0.3824 mL | 0.9561 mL |